For the year ending 2025-12-31, TNXP made $13,107K in revenue. -$124,021K in net income. Net profit margin of -946.22%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Product revenue, net | 13,107 | |||
| Cost of sales | 6,640 | |||
| Research and development | 44,486 | |||
| Selling, general and administrative | 87,684 | |||
| Total operating expenses | 138,810 | |||
| Operating loss | -125,703 | |||
| Grant income | 3,012 | |||
| Loss on extinguishment of debt | -2,092 | |||
| Interest income | 4,146 | |||
| Interest expense | 89 | |||
| Other expense, net | -3,295 | |||
| Net loss available to common stockholders | -124,021 | |||
| Basic EPS | -14.57 | |||
| Diluted EPS | -14.57 | |||
| Basic Average Shares | 8,511,318 | |||
| Diluted Average Shares | 8,511,318 | |||
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)